Cellular Basis for Therapeutic Choices in Heart Failure
- 26 October 2004
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (17) , 2559-2561
- https://doi.org/10.1161/01.cir.0000146803.14063.f7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failureJournal of the American College of Cardiology, 2004
- Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic DysfunctionCirculation, 2004
- Cardiac Metabolism as a Target for the Treatment of Heart FailureCirculation, 2004
- Valsartan Restores Sarcoplasmic Reticulum Function With No Appreciable Effect on Resting Cardiac Function in Pacing-Induced Heart FailureCirculation, 2004
- A Guide for the PerplexedCirculation, 2003
- Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human HeartCirculation, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Aldosterone and Spironolactone in Heart FailureNew England Journal of Medicine, 1999
- Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitroCell, 1993
- Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.Heart, 1987